secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001193125-23-002980
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio sells Rare Pediatric Disease PRV to Bristol-Myers Squibb for $95M cash
--------------------------------------------------------------------------------

- Sold PRV awarded for ZYNTEGLO (betibeglogene autotemcel) for β-thalassemia to Bristol-Myers Squibb.
- Total purchase price of $95 million paid in cash at closing on January 5, 2023.
- Sale closed simultaneously with execution of Asset Purchase Agreement; no assumed liabilities.
- Proceeds provide capital infusion; no specific use of proceeds disclosed.
- PRV transfer required FDA notification within 14-30 days post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/0001193125-23-002980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/d435443d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer